CRONOS GROUP INC(NASDAQ:CRON) stock Fundamental Analysis

Fundamental Rating

Overall CRON gets a fundamental rating of 5 out of 10. We evaluated CRON against 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRON had negative earnings in the past year.

In the past year CRON had a positive cash flow from operations.

In the past 5 years CRON reported 4 times negative net income.

CRON had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CRON's Return On Assets of -4.01% is fine compared to the rest of the industry. CRON outperforms 77.30% of its industry peers.

Looking at the Return On Equity, with a value of -4.39%, CRON belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-4.01%
ROE	-4.39%
ROIC	N/A

ROA(3y)-16.25%

ROA(5y)0.65%

ROE(3y)-17.03%

ROE(5y)2.26%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CRON has a Gross Margin of 14.66%. This is comparable to the rest of the industry: CRON outperforms 50.81% of its industry peers.

In the last couple of years the Gross Margin of CRON has declined.

CRON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	14.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-23.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CRON remains at a similar level compared to 1 year ago.

The number of shares outstanding for CRON has been increased compared to 5 years ago.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRON has an Altman-Z score of 5.67. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

CRON has a better Altman-Z score (5.67) than 82.70% of its industry peers.

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	5.67

ROIC/WACCN/A

WACC8.51%

2.3 Liquidity

A Current Ratio of 24.24 indicates that CRON has no problem at all paying its short term obligations.

The Current ratio of CRON (24.24) is better than 94.05% of its industry peers.

CRON has a Quick Ratio of 23.05. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 23.05, CRON belongs to the best of the industry, outperforming 93.51% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	24.24
Quick Ratio	23.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.78% over the past year.

CRON shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.05%.

Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 48.40% on average per year.

EPS 1Y (TTM)77.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%663.28%

Revenue 1Y (TTM)28.05%

Revenue growth 3Y23.14%

Revenue growth 5Y48.4%

Sales Q2Q%38.11%

3.2 Future

Based on estimates for the next years, CRON will show a small growth in Earnings Per Share. The EPS will grow by 6.17% on average per year.

CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.82% yearly.

EPS Next Y7.27%

EPS Next 2Y43.59%

EPS Next 3Y-18.62%

EPS Next 5Y6.17%

Revenue Next Year38.35%

Revenue Next 2Y28%

Revenue Next 3Y13.41%

Revenue Next 5Y7.82%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRON. In the last year negative earnings were reported.

A Price/Forward Earnings ratio of 289.56 indicates a quite expensive valuation of CRON.

Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 72.43% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, CRON is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	289.56

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CRON is valued cheaper than 80.54% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	42.77
EV/EBITDA	N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRON does not grow enough to justify the current Price/Earnings ratio.

A cheap valuation may be justified as CRON's earnings are expected to decrease with -18.62% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y43.59%

EPS Next 3Y-18.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

NASDAQ:CRON (2/21/2025, 9:09:18 PM)

After market: 1.98 +0.01 (+0.51%)

1.97

+0.03 (+1.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)03-04 2025-03-04/amc

Inst Owners14.79%

Inst Owner Change5.51%

Ins Owners5.46%

Ins Owner Change0.58%

Market Cap753.58M

Analysts74.55

Price Target2.56 (29.95%)

Short Float %1.88%

Short Ratio2.54

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-194.12%

Min EPS beat(2)-684.31%

Max EPS beat(2)296.08%

EPS beat(4)2

Avg EPS beat(4)-124.67%

Min EPS beat(4)-684.31%

Max EPS beat(4)296.08%

EPS beat(8)4

Avg EPS beat(8)-80.2%

EPS beat(12)5

Avg EPS beat(12)-76.45%

EPS beat(16)7

Avg EPS beat(16)-67.51%

Revenue beat(2)2

Avg Revenue beat(2)7%

Min Revenue beat(2)4.28%

Max Revenue beat(2)9.73%

Revenue beat(4)3

Avg Revenue beat(4)2.14%

Min Revenue beat(4)-7.38%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)-0.46%

Revenue beat(12)6

Avg Revenue beat(12)-2.72%

Revenue beat(16)8

Avg Revenue beat(16)-1.63%

PT rev (1m)0.53%

PT rev (3m)-2.67%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)5.66%

EPS NY rev (3m)7.41%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)33.58%

Revenue NY rev (1m)1.5%

Revenue NY rev (3m)9.94%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	289.56
P/S	6.78
P/FCF	42.77
P/OCF	26.97
P/B	0.7
P/tB	0.73
EV/EBITDA	N/A

EPS(TTM)-0.06

EYN/A

EPS(NY)0.01

Fwd EY0.35%

FCF(TTM)0.05

FCFY2.34%

OCF(TTM)0.07

OCFY3.71%

SpS0.29

BVpS2.83

TBVpS2.72

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.01%
ROE	-4.39%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	14.66%
FCFM	15.84%

ROA(3y)-16.25%

ROA(5y)0.65%

ROE(3y)-17.03%

ROE(5y)2.26%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-23.24%

F-Score6

Asset Turnover0.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	129.19%
Cap/Sales	9.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	24.24
Quick Ratio	23.05
Altman-Z	5.67

F-Score6

WACC8.51%

ROIC/WACCN/A

Cap/Depr(3y)49.62%

Cap/Depr(5y)329.4%

Cap/Sales(3y)8.38%

Cap/Sales(5y)52.98%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)77.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%663.28%

EPS Next Y7.27%

EPS Next 2Y43.59%

EPS Next 3Y-18.62%

EPS Next 5Y6.17%

Revenue 1Y (TTM)28.05%

Revenue growth 3Y23.14%

Revenue growth 5Y48.4%

Sales Q2Q%38.11%

Revenue Next Year38.35%

Revenue Next 2Y28%

Revenue Next 3Y13.41%

Revenue Next 5Y7.82%

EBIT growth 1Y28.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year55.67%

EBIT Next 3Y11.15%

EBIT Next 5Y10.5%

FCF growth 1Y116.72%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y127.8%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens